Topics

Amgen, Pfizer biosimilar sales pressure top drugs

07:03 EST 31 Jan 2020 | BioPharmaDive

Competition is heating up for copycats to Roche's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting.

Original Article: Amgen, Pfizer biosimilar sales pressure top drugs

NEXT ARTICLE

More From BioPortfolio on "Amgen, Pfizer biosimilar sales pressure top drugs"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...